TD Cowen Forecasts Strong Price Appreciation for McKesson (NYSE:MCK) Stock

McKesson (NYSE:MCK) had its price target lifted by research analysts at TD Cowen from $1,006.00 to $1,200.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen‘s price objective points to a potential upside of 13.12% from the company’s current price.

Several other analysts also recently commented on MCK. Mizuho boosted their target price on shares of McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 20th. Wall Street Zen upgraded shares of McKesson from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Barclays lifted their price objective on shares of McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. UBS Group increased their target price on shares of McKesson from $1,080.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Friday, October 16th. Finally, Robert W. Baird set a $1,015.00 target price on McKesson in a report on Thursday, August 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,026.18.

McKesson Stock Performance

Shares of NYSE:MCK traded down $11.21 during midday trading on Thursday, hitting $1,060.79. 812,129 shares of the stock were exchanged, compared to its average volume of 691,239. McKesson has a 52-week low of $723.68 and a 52-week high of $1,121.50. The business’s fifty day simple moving average is $938.13 and its two-hundred day simple moving average is $868.12. The company has a market capitalization of $123.68 billion, a PE ratio of 27.28, a P/E/G ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The firm had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. During the same quarter last year, the firm earned $9.86 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. As a group, equities analysts anticipate that McKesson will post 45.26 EPS for the current year.

Insider Activity

In other news, Director Bradley Lerman sold 301 shares of McKesson stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Francisco Fraga sold 650 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00. Following the transaction, the executive vice president directly owned 4,414 shares of the company’s stock, valued at $4,868,465.44. This represents a 12.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,462 shares of company stock valued at $2,511,106. 0.06% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MCK. Nvwm LLC raised its stake in McKesson by 933.3% during the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 28 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in McKesson in the 2nd quarter worth $27,000. Trellis Wealth Advisors LLC acquired a new stake in McKesson in the 3rd quarter worth $32,000. Clearstead Trust LLC acquired a new stake in McKesson in the 2nd quarter worth $37,000. Finally, GK Wealth Management LLC bought a new position in shares of McKesson during the 3rd quarter worth about $38,000. 85.07% of the stock is owned by institutional investors.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.